Upgrade to SI Premium - Free Trial

Sanofi (SNY), Regeneron (REGN) Report FDA Priority Review Acceptance of Supplemental Biologics License Application for Dupixent

November 6, 2018 8:18 AM
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Management Comments

Next Articles